[ad_1]
By Geoff Percival
Amryt Pharma, an Irish orphan drug company, plans to expand its portfolio of treatments for rare diseases.
In an update of its turnover, growth reached 14 million euros. During the year, Amryt stated that it was actively seeking new business badets that could benefit from the company's established commercial, medical and regulatory infrastructure. "We are very well positioned to continue to build and make Amryt a world leader in rare and orphan diseases," said Joe Wiley, CEO of the company, in 1969.
19659003] [19659003] Amryt currently has two main strengths – the commercial drug Lojuxta, which treats a potentially fatal disorder causing abnormally high levels of "bad" cholesterol, and the developmental drug AP101, which is considered Epidermolysis Bullosa (EB).
Amryt recently followed a number of international distribution agreements for Lojuxta with his first "repayment" agreement, with the British NHS, which sees drugs delivered to patients via their health services.
The company reported that the Phase 3 clinical trials for AP101 are progressing well, with an interim efficacy badysis expected to be completed in the last quarter of this year and high-level data from the tests. second quarter of next year, the EB treatment market is expected to establish at around 1 billion euros.
"The first half-year turnover of 7 million euros is in line with expectations and we believe that revenue growth continue to build in the second half, with growth organic backed by distributor markets and repayment, "said Andrew Young of Davy.
[ad_2]
Source link
